Last 12 months
Inside the activity.
0 purchase rows · 38 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 22 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2017 Filed Dec 20, 2017 23:55 UTC |
Freitag Gregory GeneDirector · General Counsel & SVP BD
|
GrantEmployee Stock Option (right to purchase) · Derivative | 22,100 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015746 · edgar.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
Hansen David KChief Accounting Officer
|
GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015745 · edgar.xml · derivative · entry 2 Hansen David K · CIK 0001362545 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
Hansen David KChief Accounting Officer
|
GrantEmployee Stock Option (right to purchase) · Derivative | 8,600 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015745 · edgar.xml · derivative · entry 1 Hansen David K · CIK 0001362545 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 Underlying: Common Stock · 8,600 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
Donovan Michael PatrickVP Operations
|
GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015744 · edgar.xml · derivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
Donovan Michael PatrickVP Operations
|
GrantEmployee Stock Option (right to purchase) · Derivative | 9,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015744 · edgar.xml · derivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantRestricted Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015743 · edgar.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantEmployee Stock Option (right to purchase) · Derivative | 13,900 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015743 · edgar.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 Underlying: Common Stock · 13,900 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015742 · edgar.xml · derivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
GrantEmployee Stock Option (right to purchase) · Derivative | 9,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015742 · edgar.xml · derivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
Leach KevinVice President Marketing
|
GrantRestricted Stock Units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015741 · edgar.xml · derivative · entry 2 Leach Kevin · CIK 0001668805 · Vice President Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
Leach KevinVice President Marketing
|
GrantEmployee Stock Option (right to purchase) · Derivative | 8,250 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015741 · edgar.xml · derivative · entry 1 Leach Kevin · CIK 0001668805 · Vice President Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
MCCARREY SHAWN FSVP Sales
|
GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015740 · edgar.xml · derivative · entry 2 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
MCCARREY SHAWN FSVP Sales
|
GrantEmployee Stock Option (right to purchase) · Derivative | 9,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015740 · edgar.xml · derivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
Gingrich Jon S.Chief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015739 · edgar.xml · derivative · entry 2 Gingrich Jon S. · CIK 0001711638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
Gingrich Jon S.Chief Commercial Officer
|
GrantEmployee Stock Option (right to purchase) · Derivative | 32,600 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015739 · edgar.xml · derivative · entry 1 Gingrich Jon S. · CIK 0001711638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,600 Underlying: Common Stock · 32,600 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
MARIANI PETER JChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 7,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015738 · edgar.xml · derivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC |
MARIANI PETER JChief Financial Officer
|
GrantEmployee Stock Option (right to purchase) · Derivative | 45,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015738 · edgar.xml · derivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:52 UTC |
Zaderej Karen L.Director · CEO
|
GrantRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015737 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:52 UTC |
Zaderej Karen L.Director · CEO
|
GrantEmployee Stock Option (right to purchase) · Derivative | 75,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015737 · edgar.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 00:45 UTC |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 16,585 | $26.34 | $436,848.90 |
DisclosureSEC source: 0001179110-17-015344 · edgar.xml · nonDerivative · entry 2 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,607 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.10 to $26.90. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: These shares of common stock include 107,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| December 11, 2017 Filed Dec 14, 2017 00:45 UTC |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 21,820 | $26.35 | $574,957.00 |
DisclosureSEC source: 0001179110-17-015344 · edgar.xml · nonDerivative · entry 1 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,192 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017 (the "Plan"). All shares pursuant to the Plan have been sold as of the last sales reported herein. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.65. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: These shares of common stock include 108,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 23:30 UTC |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 31,805 | $26.37 | $838,697.85 |
DisclosureSEC source: 0001179110-17-015168 · edgar.xml · nonDerivative · entry 3 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,312 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.15 to $26.70. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: These shares of common stock include 108,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| December 08, 2017 Filed Dec 14, 2017 00:44 UTC Amendment |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 31,805 | $26.37 | $838,697.85 |
DisclosureSEC source: 0001179110-17-015343 · edgar.xml · nonDerivative · entry 3 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,012 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.15 to $26.70. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: These shares of common stock include 108,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. F7 · balance_after: Amended as a result of 2,300 shares sold on December 7, 2017 inadvertently not being disclosed. Such December 7, 2017 transaction has been revised resulting in a change in the aggregate number of shares sold and the weighted average sale price for such day, along with change in holdings after the December 7 and 8, 2017 transactions. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 23:30 UTC |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 31,200 | $26.50 | $826,800.00 |
DisclosureSEC source: 0001179110-17-015168 · edgar.xml · nonDerivative · entry 2 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,117 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.95. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| December 07, 2017 Filed Dec 14, 2017 00:44 UTC Amendment |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 33,500 | $26.47 | $886,745.00 |
DisclosureSEC source: 0001179110-17-015343 · edgar.xml · nonDerivative · entry 2 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,817 F7 · shares: Amended as a result of 2,300 shares sold on December 7, 2017 inadvertently not being disclosed. Such December 7, 2017 transaction has been revised resulting in a change in the aggregate number of shares sold and the weighted average sale price for such day, along with change in holdings after the December 7 and 8, 2017 transactions. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.95. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: Amended as a result of 2,300 shares sold on December 7, 2017 inadvertently not being disclosed. Such December 7, 2017 transaction has been revised resulting in a change in the aggregate number of shares sold and the weighted average sale price for such day, along with change in holdings after the December 7 and 8, 2017 transactions. F2 · balance_after: These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. F7 · balance_after: Amended as a result of 2,300 shares sold on December 7, 2017 inadvertently not being disclosed. Such December 7, 2017 transaction has been revised resulting in a change in the aggregate number of shares sold and the weighted average sale price for such day, along with change in holdings after the December 7 and 8, 2017 transactions. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 23:30 UTC |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 21,290 | $26.22 | $558,223.80 |
DisclosureSEC source: 0001179110-17-015168 · edgar.xml · nonDerivative · entry 1 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,317 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $27.00. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| December 06, 2017 Filed Dec 14, 2017 00:44 UTC Amendment |
Grooms Jamie MarkDirector
|
SaleCommon Stock | 21,290 | $26.22 | $558,223.80 |
DisclosureSEC source: 0001179110-17-015343 · edgar.xml · nonDerivative · entry 1 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,317 F6 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $27.00. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 20:31 UTC |
EW Healthcare Partners, L.P.10% owner
|
SaleCommon Stock | 1,150,000 | $19.74 | $22,701,000.00 |
DisclosureSEC source: 0000899243-17-027156 · doc4.xml · nonDerivative · entry 1 Essex Woodlands Fund IX, L.P. · CIK 0001612343 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711,111 Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 20:31 UTC |
NEELS GUIDO JDirector
|
SaleCommon Stock | 1,150,000 | $19.74 | $22,701,000.00 |
DisclosureSEC source: 0000899243-17-027155 · doc4.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Essex Woodlands Fund IX, L.P. Disclosed balance after: 3,371,111 F1 · balance_after: The reported shares are owned directly by Essex Woodlands Fund IX, L.P., a limited partnership of which Essex Woodlands Fund IX-GP, L.P., is the general partner, and of which Essex Woodlands Fund IX, LLC is the general partner. The reporting person is an owner of a limited partnership interest in Essex Woodlands Fund IX, LLC. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 16:22 UTC |
Gold Mark StephenDirector
|
Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001179110-17-014147 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 16:22 UTC |
Gold Mark StephenDirector
|
Exercise / conversionCommon Stock | 15,000 | $5.09 | $76,350.00 |
DisclosureSEC source: 0001179110-17-014147 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock for Dr. Gold include 197,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. F1 · ownership.direct: The shares of common stock for Dr. Gold include 197,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:56 UTC |
Grooms Jamie MarkDirector
|
Exercise / conversionDirector Stock Option (right to purchase) · Derivative | 3,197 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-17-013746 · edgar.xml · derivative · entry 4 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,197 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:56 UTC |
Grooms Jamie MarkDirector
|
Exercise / conversionDirector Stock Option (right to purchase) · Derivative | 11,182 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-17-013746 · edgar.xml · derivative · entry 3 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,182 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:56 UTC |
Grooms Jamie MarkDirector
|
Tax withholdingCommon Stock | 189 | $20.60 | $3,893.40 |
DisclosureSEC source: 0001179110-17-013746 · edgar.xml · nonDerivative · entry 2 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,607 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 14,397 shares by means of a cashless exercise. A cashless exercise is a method of exercising a stock option in which the option holder pays the exercise price using shares the reporting person would have received pursuant to the option exercise. As a result of this cashless exercise, the Reporting Person, on a net basis, acquired ownership of an additional 14,190 shares of common stock. F2 · balance_after: These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:56 UTC |
Grooms Jamie MarkDirector
|
Exercise / conversionCommon Stock | 14,379 | $0.27 | $3,882.33 |
DisclosureSEC source: 0001179110-17-013746 · edgar.xml · nonDerivative · entry 1 Grooms Jamie Mark · CIK 0001530935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 14,397 shares by means of a cashless exercise. A cashless exercise is a method of exercising a stock option in which the option holder pays the exercise price using shares the reporting person would have received pursuant to the option exercise. As a result of this cashless exercise, the Reporting Person, on a net basis, acquired ownership of an additional 14,190 shares of common stock. F2 · balance_after: These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 16,829 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 11 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,829 shares Expires 2018-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 4,375 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 10 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 4,375 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 5,313 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 9 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187 Underlying: Common Stock · 5,313 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 1,250 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 8 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires 2023-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 40,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 7 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 16,829 | $1.07 | $18,007.03 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 6 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 4,375 | $4.81 | $21,043.75 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 5 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 5,313 | $3.67 | $19,498.71 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 1,250 | $5.45 | $6,812.50 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Tax withholdingCommon Stock | 5,480 | $20.00 | $109,600.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,185 F1 · shares: This Form is being filed in part to report the exercise of a stock option for a total of 40,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 34,520 shares of common stock. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 40,000 | $2.74 | $109,600.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed in part to report the exercise of a stock option for a total of 40,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 34,520 shares of common stock. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:22 UTC |
Freitag Gregory GeneDirector · General Counsel & SVP BD
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 10,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-012731 · edgar.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 10,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:22 UTC |
Freitag Gregory GeneDirector · General Counsel & SVP BD
|
Tax withholdingCommon Stock | 1,450 | $18.90 | $27,405.00 |
DisclosureSEC source: 0001179110-17-012731 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,666 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 10,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 8,550 shares of common stock. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:22 UTC |
Freitag Gregory GeneDirector · General Counsel & SVP BD
|
Exercise / conversionCommon Stock | 10,000 | $2.74 | $27,400.00 |
DisclosureSEC source: 0001179110-17-012731 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 10,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 8,550 shares of common stock. Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 20:02 UTC |
Rudelius Robert JamesDirector
|
SaleCommon Stock | 16,143 | $18.00 | $290,574.00 |
DisclosureSEC source: 0001179110-17-012194 · edgar.xml · nonDerivative · entry 3 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,273 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.